Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin for Gram-Positive Osteomyelitis or Joint Infections
NCT03426761Phase 4Completed
- Sponsor
- Infectious Diseases Physicians
- Start
- Jan 2018
- Primary completion
- Dec 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dalbavancin in osteomyelitis (OM), septic arthritis, prosthetic joint infection (PJI), sponsored by Infectious Diseases Physicians. Started Jan 2018; status: completed.
02
Drugs
dalbavancin
03
Conditions
osteomyelitis (OM)septic arthritisprosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT03426761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03426761.